title: Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women.
abstract: Postmenopausal estrogen use is associated with a reduced risk of heart disease and hip fracture; in observational studies, different behaviors among hormone users and nonusers may partially explain these results. We examined risk of cardiovascular disease and hip fracture with medium-potency compared with low-potency or short-term estrogen use, and the effect of added progestin, among 9,236 women in Uppsala, Sweden, who responded to a mailed questionnaire in 1987-1988. Using population registries, we identified 213 cases of myocardial infarction, 289 strokes, and 114 hip fractures from 1987-1995. We found a reduced risk of myocardial infarction for medium-potency compared with low-potency or short-term estrogen use (relative risk = 0.75, 95% confidence interval (CI) = 0.56-0.99), with a similar decrease in the subgroup that took estrogens with progestin (RR = 0.69, 95% CI = 0.45-0.90). There was no relation of medium-potency estrogen to stroke (RR = 0.91, 95% CI = 0.71-1.17, and RR = 0.81, 95% CI = 0.61-1.10 for the subgroup taking progestin), and no effect of duration on either heart disease or stroke. We observed a reduction in hip fractures for medium-potency use (RR = 0.65, 95% CI = 0.45-0.95), and for use of combined estrogen-progestin therapy (RR = 0.64, 95% CI = 0.41-1.00). These data support a decreased risk of heart disease and hip fracture for medium-potency estrogen use alone or with progestin; self-selection to hormone use cannot explain these reductions.
authors.affiliation: Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, MA 02115, USA.
authors.forename: F
authors.initials: F
authors.lastname: Grodstein
authors.forename: M J
authors.initials: MJ
authors.lastname: Stampfer
authors.forename: M
authors.initials: M
authors.lastname: Falkeborn
authors.forename: T
authors.initials: T
authors.lastname: Naessen
authors.forename: I
authors.initials: I
authors.lastname: Persson
mesh_terms: D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000517:prevention & control; D016001:Confidence Intervals; D015914:Estrogen Replacement Therapy / Q000009:adverse effects / Q000706:statistics & numerical data*; D005260:Female; D005500:Follow-Up Studies; D006620:Hip Fractures / Q000453:epidemiology* / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D016017:Odds Ratio; D011372:Progestins / Q000008:administration & dosage*; D016016:Proportional Hazards Models; D018570:Risk Assessment; D015983:Selection Bias; D013548:Sweden / Q000453:epidemiology
chemical_list: D011372:Progestins